Physician profile
Kyle Aaron Luke
NPI 1841878212
$389.33
in general payments reported to CMS, 2019-2025
9 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $126 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.28 | 2025 | Jardiance |
| Melinta Therapeutics, LLC | $72.58 | 2024-2025 | Orbactiv, Kimyrsa, Rezzayo |
| Merck Sharp & Dohme LLC | $68.99 | 2024-2025 | Zerbaxa, Dificid, Recarbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.82 | 2025 | Xifaxan |
| Stryker Corporation | $29.57 | 2025 | Flowtriever |
| Recor Medical INC | $25.11 | 2024 | Paradise Renal Denervation System |
| Alexion Pharmaceuticals, INC. | $19.36 | 2025 | Ultomiris |
| Amgen INC. | $18.58 | 2024 | |
| Gilead Sciences, INC. | $16.04 | 2025 | Veklury |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Luke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.